Skip Navigation

NIH VideoCasting

CIT can broadcast your seminar, conference or meeting live to a world-wide audience over the Internet as a real-time streaming video. The event can be recorded and made available for viewers to watch at their convenience as an on-demand video or a downloadable file. CIT can also broadcast NIH-only or HHS-only content.

CANCELLED - Metabolic Barriers to Effective Cancer Immunotherapy (HHS Only)

Air date: Friday, December 6, 2019, 12:00:00 PM
Time displayed is Eastern Time, Washington DC Local
Description: NCI’s Center for Cancer Research (CCR) Grand Rounds

Dr. Delgoffe is a tenured Associate Professor of Immunology at the University of Pittsburgh School of Medicine and the University of Pittsburgh Medical Center Hillman Cancer Center. Dr. Delgoffe graduated summa cum laude from Western Michigan University in 2004 before completing doctoral training at the Johns Hopkins School of Medicine in 2010. His Ph.D research, under the direction of Dr. Jonathan Powell, made seminal discoveries regarding the role of nutrient sensing in T cell function and fate, resulting in several first-author contributions in high impact journals. He then went on to complete postdoctoral training at St. Jude Children’s Research Hospital with Dr. Dario Vignali in 2011, where he delineated signaling pathways important for the function of regulatory T cells, immunosuppressive cells important for maintaining a tolerogenic environment in cancer. His work was published in Nature and Nature Immunology, supported by an NRSA F32 fellowship, and led to the development of novel immunotherapeutics for cancer currently in phase I clinical trials. He began his own research group within the Tumor Microenvironment Center in Pittsburgh in 2014, aiming to understanding the metabolic nature of immune suppression in cancer. Since its inception, his laboratory has made fundamental observations regarding the immune system’s metabolic status during cancer progression. Further, his group has demonstrated (and continues to explore) that these defects are attractive targets to improve cancer immunotherapy. Working with clinical partners, he has translated several of his observations into funded and accruing clinical trials at UPMC, while continuing to excel in academic discovery. He has received several awards for his commitment to innovation and translation and has been invited to give multiple plenary talks at national and international meetings. Further, his research group has had success competing for funding from government, foundation, and corporate sources. For more information about the speaker, please visit
Author: Greg Delgoffe, Ph.D., Assistant Professor, Department of Immunology, University of Pittsburgh
Runtime: 1 hour